| Literature DB >> 29538420 |
Alexandra Wollum1, Rose Gabert1, Claire R McNellan1, Jessica M Daly2, Priscilla Reddy3, Paurvi Bhatt2, Miranda Bryant1, Danny V Colombara1, Pamela Naidoo3, Belinda Ngongo2,4, Anam Nyembezi3, Zaino Petersen3, Bryan Phillips1, Shelley Wilson1, Emmanuela Gakidou1, Herbert C Duber1.
Abstract
BACKGROUND: The HealthRise initiative seeks to implement and evaluate innovative community-based strategies for diabetes, hypertension and hypercholesterolemia along the entire continuum of care (CoC)-from awareness and diagnosis, through treatment and control. In this study, we present baseline findings from HealthRise South Africa, identifying gaps in the CoC, as well as key barriers to care for non-communicable diseases (NCDs).Entities:
Mesh:
Year: 2018 PMID: 29538420 PMCID: PMC5851537 DOI: 10.1371/journal.pone.0192603
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1The continuum of care framework.
Facility sample by district and platform.
| Platform | Umgungundlovu | Pixley ka Seme |
|---|---|---|
| Hospital | 3 | 3 |
| Community Health Centre (CHC) | 6 | 8 |
| Primary Health Centre (PHC) | 18 | 28 |
| Mobile clinic | 9 | 0 |
| Satellite clinic | 0 | 4 |
| General private practitioner clinic | 3 | 0 |
| Private pharmacy | 4 | 0 |
| Total | 43 | 43 |
Interview and focus group participants.
| Interviewees | Umgungundlovu | Pixley ka Seme |
|---|---|---|
| CCGs | 2 interviews | 1 interviews |
| Healthcare Providers: PHC doctors, Public GP | 6 interviews | 3 interviews |
| Health facility managers or policy maker | 1 interviews | 2 interviews |
| NGO Officials | 1 interview | 1 interview |
| Nurses | 2 interview | 3 interviews |
| General Community Members | 5 FGD | 4 FGD |
| NCD Patients | 4 FGD | 2 FGD |
| Total | 11 interviews / 9 FGD | 10 interviews / 6 FGD |
*CCG-community care giver
**GP-general practitioner
Items included in facility capacity analysis.
| Category | Diabetes | Hypertension |
|---|---|---|
| Pharmaceuticals | insulin, aspirin, statins, ACE Inhibitors, biguanides and sulphonylureas | insulin, aspirin, statins, ACE Inhibitors, thiazide diuretic, calcium channel blockers and beta blockers |
| Testing Capacity equipment | scale, blood pressure apparatus, plasma glucose tests or glucometers and blood glucose strips, urinalysis, total cholesterol test or fasting lipid profile or LDL cholesterol test, creatinine test (eGFR) and HbA1c test | scale, blood pressure apparatus, plasma glucose tests or glucometers and blood glucose strips, creatinine tests (eGFR), urinalysis and total cholesterol test or fasting lipid profile or LDL cholesterol test. |
| Guidelines | PC101 or disease specific treatment guidelines and EML. | PC101 or disease specific treatment guidelines and EML. |
Population characteristics and risk factors.
| Umgungundlovu | Pixley ka Seme | |
|---|---|---|
| Race Group | ||
| Black African | 84.8 (84.5,85.0) | 30.8 (30.1,31.5) |
| Coloured | 2.1 (2.0,2.2) | 59.4 (58.7,60.2) |
| Indian or Asian | 6.7 (6.5,6.9) | 0.5 (0.4,0.6) |
| White | 6.2 (6.1,6.4) | 8.4 (7.9,8.8) |
| Age Distribution | ||
| 0–14 | 28.2 (27.9,28.5) | 31.7 (31.0,32.4) |
| 15–64 | 66.5 (66.1,66.8) | 62.2 (61.5,63.0) |
| 65+ | 5.4 (5.2,5.5) | 6.0 (5.7,6.4) |
| Female | 52.3 (52.0,52.6) | 50.9 (50.1,51.7) |
| Disease Prevalence | ||
| Diabetes | 11.0 (7.2,14.9) | 9.7 (5.1,14.2) |
| Hypertension | 46.8 (41.2,52.3) | 51.0 (44.3,57.6) |
| Hypercholesterolemia | 11.1 (7.4,14.8) | 17.3 (10.9,23.7) |
| Risk Factors | ||
| Binge drank alcohol in past week | 19.9 (15.3,24.5) | 26.7 (20.2,33.2) |
| Inactive | 40.5 (33.7,47.3) | 39.1 (31.1,47.1) |
| BMI ≥ 25 | 55.3 (49.8,60.8) | 54.8 (47.3,62.4) |
| Current smoker | 18.1 (13.5,22.8) | 35.2 (27.8,42.6) |
* Derived from 2011 municipal census data (23, 24).
^ Estimated using 2012 South Africa National Health and Nutrition Examination Survey (SANHANES)
Fig 2Estimating the continuum of care for (a) diabetes, (b) hypertension and (c) hypercholesterolemia in Umgungundlovu and Pixley ka Seme.
Fig 3Percent of items available at facilities for (a) diabetes and (b) hypertension as per national guidelines.